Repligen Corp (RGEN) Stock Analysis
Verdict: HOLD
High-multiple growth recovery is supported by recurring bioprocessing demand, but 166x P/E leaves zero room for guidance disappointments.
Investment score: 64/100
Analysis as of
Is Repligen Corp stock worth reviewing? AI model thesis
Repligen is executing a fundamental turnaround with four straight earnings beats and raised 2026 outlooks. However, the valuation has front-run the recovery, trading at nearly triple the EBITDA multiple of its peers. The model sees a high-quality company at a prohibitive price point.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 70/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Repligen Corp opportunities and risks
What speaks for RGEN
- Recovery in Bioprocessing Orders
What speaks against RGEN
- Severe Valuation Premium vs Peers
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RGEN | 196.4x | 10.4x | 85.7x | 24.7% | 5.3% | 1.4% |
| CRL | n/a | 2.9x | 49.7x | 31.9% | -4.6% | 3.4% |
| TECH | 101.5x | 9.3x | 44.1x | 65.0% | 9.0% | 2.4% |
| BRKR | n/a | 2.8x | 36.7x | 45.6% | -0.3% | 0.5% |
| BIO | 54.2x | 3.5x | 20.9x | 51.9% | 6.5% | 4.0% |
| AVTR | n/a | 1.3x | 416.8x | 31.8% | -8.8% | 5.2% |
| Peer median | n/a | 2.9x | 44.1x | 45.6% | -0.3% | 3.4% |
Frequently asked questions about Repligen Corp (RGEN)
Is RGEN stock a good investment?
The cached TradeMates AI model rates Repligen Corp as HOLD with an investment score of 64/100. Repligen is executing a fundamental turnaround with four straight earnings beats and raised 2026 outlooks. However, the valuation has front-run the recovery, trading at nearly triple the EBITDA multiple of its peers. The model sees a high-quality company at a prohibitive price point. This is algorithmic model output, not personal investment advice.
Is RGEN stock a buy?
The TradeMates model verdict for RGEN is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.